15TH INTERNATIONAL THYROID CONGRESS PROGRAM AND MEETING ABSTRACTS
2015; Mary Ann Liebert, Inc.; Volume: 25; Issue: S1 Linguagem: Inglês
10.1089/thy.2015.29004.abstracts
ISSN1557-9077
Tópico(s)Congenital Diaphragmatic Hernia Studies
ResumoThyroidVol. 25, No. S1 AbstractsOpen Access15TH INTERNATIONAL THYROID CONGRESS PROGRAM AND MEETING ABSTRACTSPublished Online:14 Oct 2015https://doi.org/10.1089/thy.2015.29004.abstractsAboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail 15th International Thyroid Congress Scientific Program – Sunday, October 186:30 AM – 8:30 PM15th ITC Registration Open Convention Foyer 1/2Lobby/Third Level6:30 AM – 6:30 PMSpeaker Ready Room Open (open to meeting faculty only) Australia 2 RoomLobby/Third Level7:00 AM – 5:15 PMEndocrine Neck Advanced Ultrasound Course with Practicum(Satellite Program, separate registration required) Asia 4 RoomLobby/Third Level8:00 AM – 4:00 PME. Chester Ridgway (Ridgway) Clinical Trainee Conference(Pre-registration required for Sunday's pre-conference programming; full agenda available in trainees section of program book)The Ridgway Trainee Conference is named to memorialize Dr. E. Chester "Chip" Ridgway, for his large contributions to the field of thyroidology, his great devotion to education of fellows over many years, and especially to honor his creation and establishment of a full day seminar led by thyroid experts teaching the full breadth of thyroid-related endocrine subjects. The ATA Annual Meeting trainee track has been combined with the Endocrine Fellows Conference to serve clinical, basic, surgical and pediatric endocrine fellows and trainees. The Ridgway legacy fund, supported by colleagues, fellows and friends of Dr. E. Chester Ridgway is to be of continuing support to the Ridgway Trainee Conference. Southern Hemisphere IV-VFifth Level8:00 AM – 6:00 PM15th ITC Exhibit and Poster Hall Open(Open for exhibitor-setup only) Atlantic HallGround/First Level8:50 AM – 2:15 PMIodine Global Network Satellite Program(Satellite Program, separate registration required) Asia 3 RoomLobby/Third Level11:30 AM – 3:00 PME. Chester Ridgway (Ridgway) Basic Trainee Conference: Genomic Regulation of Gene Expression(Open to all interested ITC meeting attendees; lunch reserved for trainees only; full agenda available in trainees section of program book) Americas Seminar RoomFifth Level1:00 PM – 3:00 PMATA Alliance for Patient Education Public Forum(Open to the general public and all meeting attendees)Sponsored by the ATA Alliance members: American Thyroid Association, Bite Me Cancer, Graves' Disease and Thyroid Foundation, Light of Life Foundation, Thyca: Thyroid Cancer Survivors' Association, Thyroid Cancer Alliance, Thyroid Cancer Canada and Thyroid Federation International Asia 1 RoomLobby/Third Level5:15 PM – 5:45 PM15th ITC Welcome CeremonyIntroduction by ATA leadership, acknowledgement to all thyroid sister societies, acknowledgement to the Program Organizing CommitteeWelcome remarks byRobert C. Smallridge, President, ATAJohn C. Morris, III Secretary/COO, ATAJohn Armstrong, Surgeon General and Secretary, Florida Department of Health Northern Hemisphere BCD Fifth Level5:45 PM – 7:30 PM15th ITC Opening Session – Progress in Thyroid Research: Highlights from the Last DecadeChair: Rebecca S. Bahn Northern Hemisphere BCDFifth Level AutoimmunitySandra M. McLachlan Thyroid CancerMartin Schlumberger Thyroid Hormone ActionDouglas Forrest Clinical ThyroidologyDavid S. Cooper 7:30 PM – 9:00 PM15th ITC Welcome Reception(Meeting registration/badge required for entry) Swan and Dolphin Pool and Beach Area (Outside)15th International Thyroid Congress Scientific Program – Monday, October 196:30 AM – 5:30 PM15th ITC Registration Open Convention Foyer 1/2Lobby/Third Level6:30 AM – 5:30 PMSpeaker Ready Room Open (open to meeting faculty only) Australia 2 RoomLobby/Third Level6:30 AM – 8:00 AMEarly Riser Symposium Continental Breakfast Pacific HallGround/First Level7:00 AM – 8:20 AMEarly Riser Symposium: New Modalities in the Treatment of Medullary Thyroid Cancer (MTC)Co–Chairs: Ana O. Hoff and Laura Fugazzola Pacific HallGround/First Level Molecular Mechanisms of MTCRui M. B. Maciel Targeted Therapeutic Agents for MTCRossella Elisei Management of Side Effects of Long–Term Tyrosine Kinase Inhibitor TreatmentBarbara Jarzab Update on MTC GuidelinesSamuel A. Wells, Jr. 8:35 AM – 9:20 AMOpening Plenary Session: Advancing Individualized Medicine with Public–Private PartnershipsIntroduction by Robert C. SmallridgeWilliam W. ChinNorthern Hemisphere BCDFifth Level9:00 AM – 4:30 PM15th ITC Exhibit and Poster Hall Open(Open at 8:00 AM for poster presenters only) Atlantic HallGround/First Level9:20 AM – 9:45 AMPoster Review Session and Break in the Exhibit Hall Atlantic HallGround/First Level9:30 AM – 11:00 AMRidgway Trainee Conference Clinical Track: Case Discussions – Thyroid FunctionGisah CarvalhoStephanie L. LeePeter A. SingerSouthern Hemisphere IV-VFifth Level9:45 AM – 11:00 AMSymposium: Nontraditional TSHR SignalingCo–Chairs: Basil Rapoport and Syed Morshed Southern Hemisphere IFifth Level Selective TSHR Signaling by TSHR AntibodiesTerry F. Davies TSHR–Arrestin–1 Mediated PathwaysSusanne E. Neumann TSHR–IGF–1 InteractionsTerry J. Smith 9:45 AM – 11:00 AMSymposium: TR Alpha Mutations – Bench to BedsideCo–Chairs: V Krishna Chatterjee and Marcel Meima Southern Hemisphere IIFifth Level Animal ModelsSheue-yann Cheng Treatment of Animal ModelsJ.H. Duncan Bassett Human MutationsCarla Moran Treatment of PatientsRobin P. Peeters 9:45 AM – 11:00 AMSymposium: New Concepts in the Management of Thyroid NodulesCo-Chairs: Stephanie A. Fish and Finn Bennedbaek Southern Hemisphere IIIFifth Level Epidemiology of Benign Thyroid NodulesShuhang Xu Who Should Be Screened for Thyroid Nodules?Arthur B. Schneider Follow–Up of Benign Nodules?Susan J. Mandel 9:45 AM – 11:00 AMSymposium: Thyroid Cancer – Translating Basic Science Discoveries to the ClinicCo-Chairs: Edna T. Kimura and Ileana Gabriela de Rubio Northern Hemisphere BCDFifth Level Redifferentiation of RAI–Refractory Thyroid CancerJames A. Fagin Somatic Mutations Analysis for Molecular DiagnosisYuri Nikiforov Targeted TherapySophie Leboulleux 11:00 AM – 11:50 AMDD1 – Discussion/Debates Clinical: A Case-Based Discussion of International Hypothyroidism GuidelinesJacqueline JonklaasGláucia MazetoSalman RazviSouthern Hemisphere IFifth Level11:00 AM – 11:50 AMDD2 – Discussion/Debates Clinical: Targeted Therapy for Thyroid Cancer: When and What?Steven I. ShermanJohannes W.A. SmitNorthern Hemisphere BCDFifth Level11:00 AM – 11:50 AMDD3 – Discussion/Debates Clinical: Unusual Thyroid Function TestsModerator: Mark P. VanderpumpInge Bülow PedersenBrian W. KimShu WangHelton Estrela RamosNorthern Hemisphere E3-E4, Fifth Level11:00 AM – 11:50 AMDD4 – Discussions/Debates Clinical: Management of Thyroid StormHenry B. BurchTetsurou SatohNorthern Hemisphere E1-E2, Fifth Level11:00 AM – 11:50 AMDD5 – Discussion/Debates Clinical: Is There a Role for Long-Term Anti-Thyroid Drug Therapy?Stig AndersenDouglas S. RossSouthern Hemisphere IIIFifth Level11:00 AM – 11:50 AMDD6 – Discussion/Debates Basic/Translational: TSHR Activation and Its Impact on Body Composition and Graves' OrbitopathyMarian LudgateLei ZhangAmericas Seminar RoomFifth Level11:00 AM – 11:50 AMDD7 – Discussion/Debates Basic/Translational: Oxidative Stress on ThyrocytesDenise Pires De CarvalhoXavier De DekenAsia 1 RoomLobby/Third Level11:00 AM – 11:50 AMDD8 – Discussion/Debates Basic/Translational: Immunity and Thyroid Cancer: Prospects for Immune TherapyLisa ZhangMabel M. RyderNorthern Hemisphere A1-A2, Fifth Level11:00 AM – 11:50 AMDD9 – Discussion/Debates Basic/Translational: Interactions Between Hypothalamic Pituitary Thyroid Axis and Other Pituitary DysfunctionUlla Feldt–RasmussenSalvatore BenvengaNorthern Hemisphere A3-A4, Fifth Level11:00 AM – 11:50 AMDD10 – Discussion/Debates Basic/Translational: Vertebrate Models for Study of TH ActionLuca PersaniYun-Bo ShiAsia 2 RoomLobby/Third Level12:00 PM – 1:00 PMPoster Review Session and Lunch in the Exhibit Hall Atlantic HallGround/First Level12:00 PM – 1:00 PMRidgway Trainee Conference Clinical and Basic Lunch Session: How to Get your Work Published (Open to all trainees; lunch ticket required for meal)Peter A. KoppSouthern Hemisphere IV-VFifth Level12:00 PM – 1:00 PM15th ITC Expo Theater Presented by Eisai, Inc.(Only U.S. health care professionals are permitted to attend this program; space limited – first come, first served; lunch included) Atlantic HallGround/First Level1:05 PM – 1:45 PMAmerican Thyroid Association (ATA) Van Meter Prize Lecture(Awardee Announced Onsite at Time of Lecture)Established in 1930, the ATA Van Meter Award Lecture recognizes outstanding contributions to research on the thyroid gland or related subjects. The award is given each year to an investigator who is not older than the age of 45 in the year of the award. The Van Meter award winner is kept secret until the time of the award lecture during the meeting. Funded by support from Mary Ann Liebert, Inc., Publishers; and a Van Meter endowment in memory of Jacob (Jack) Robbins created by Jean Robbins in 2014.Presentation of ATA Distinguished Service Award to 2015 awardee Peter A. KoppIn recognition and honor of an ATA member who has made important and continuing contributions to the Association.John B. Stanbury Thyroid Pathophysiology Medal Presented to 2015 awardee Sheue-yann ChengIn recognition of outstanding research contributions, either conceptual or technical, to the understanding of thyroid physiology or the pathophysiology of thyroid disease, as evidenced by having a major impact on research or clinical practice related to thyroid diseases. Northern Hemisphere BCDFifth Level1:50 PM – 3:05 PMSymposium: Clinical Utility of Anti–Thyroid Antibody MeasurementsCo-Chairs: Patricia de Fatima dos Santos Teixeira and Yuji Hiromatsu Southern Hemisphere IFifth Level PregnancyAlex S. Stagnaro-Green Hashimoto's ThyroiditisMario Rotondi Graves' DiseaseEijun Nishihara 1:50 PM – 3:05 PMSymposium: TH TransportCo-Chairs: Ulrich Schweizer and Grant W. Anderson Southern Hemisphere IIFifth Level Animal Models of TH Transporter DiseaseHeike Heuer Therapeutic Studies Using Animal ModelsAlexandra M. Dumitrescu Human TH Transporter MutationsTheo J. Visser Clinical Trials in Allan Herndon Dudley SyndromeW. Edward Visser 1:50 PM – 3:05 PMSymposium: T4/T3 Combination Therapy for HypothyroidismCo-Chairs: Elizabeth A. McAninch and Birte Nygaard Southern Hemisphere IIIFifth Level Do Patients Prefer T4/T3 Therapy, and Why?Colin M. Dayan What is the Mechanism for Enhanced Weight Loss with T3?Francesco S. Celi Risks/Safety of Combination TherapyAnne R. Cappola 1:50 PM – 3:05 PMSymposium: Prognostic Assessment of Thyroid CancerCo-Chairs: Mario Vaisman and Duncan Topliss Northern Hemisphere BCDFifth Level Functional ImagingByeong-Cheol Ahn Clinical Risk StratificationFurio Pacini Real Time PrognosticationR. Michael Tuttle 2:00 PM – 5:30 PMRidgway Trainee Conference Clinical Track: Thyroid Ultrasound Course(Open to clinical travel grant trainees only) Asia 4 RoomLobby/Third Level3:05 PM – 4:00 PMPoster Review Session and Break in the Exhibit Hall Atlantic HallGround/First Level3:05 PM – 4:00 PM15th ITC Expo Theater Presented by Hoverstate(Limited seating; first-come, first served) Atlantic HallGround/First Level4:00 PM – 4:30 PMMonday Short Oral Communications 1Co-Chairs: J. Paul Banga and Susanne Neumann Southern Hemisphere IFifth Level ABSTRACT # 17 - ORBITAL FIBROBLAST HYPOXIC RESPONSE IMPACTS TISSUE REMODELING IN GRAVES' ORBITOPATHYGina–Eva Görtz ABSTRACT # 18 - REPLICATION OF GRAVES' ORBITOPATHY MOUSE MODEL IN TWO CENTRES REVEALS A LONG TERM T CELL RESPONSE TO TSH-RECEPTOR ANTIGENUtta Berchner-Pfannschmidt ABSTRACT # 19 - ORBITAL FIBROBLASTS FROM GRAVES' ORBITOPATHY PATIENTS MEET ALL CRITERIA THAT DEFINE MESENCHYMAL STEM CELLSUtta Berchner-Pfannschmidt ABSTRACT # 20 - FAILURE OF G PROTEIN ACTIVATION BY TSH RECEPTOR ANTIBODIES DICTATES THYROCYTE DEATH – IMPLICATIONS FOR AUTOIMMUNITYSyed Morshed ABSTRACT # 21 - INCREASED LEVELS BUT IMPAIRED FUNCTION OF REGULATORY B CELLS (BREG) IN HASHIMOTO'S THYROIDITIS AND ASSOCIATED AUTOIMMUNE DISORDERSMarco Centanni 4:00 PM – 4:30 PMMonday Short Oral Communications 2Co-Chairs: Marius Stan and Salvatore Benvenga Southern Hemisphere IIFifth Level ABSTRACT # 22 - DIPLOPIA, SEVERITY SCORE, AND SMOKING IMPACT QUALITY OF LIFE IN THYROID-ASSOCIATED ORBITOPATHY – A PROSPECTIVE STUDYElena Kampmann ABSTRACT # 23 - THYROID AUTOIMMUNITY AS A BIOMARKER OF OUTCOME IN WOMEN WITH BREAST CANCER – LARGE SCALE STUDY USING DATA FROM THE TAXOTERE AS ADJUVANT CHEMOTHERAPY (TACT) TRIAL (CRUK01/001)Ilaria Muller ABSTRACT # 24 - USEFULNESS OF THYROID STIMULATING ANTIBODY AT THE TIME OF ANTITHYROID DRUG WITHDRAWAL IN PREDICTING RELAPSE OF GRAVES' HYPERTHYROIDISMHyemi Kwon ABSTRACT # 25 - GWAS OF GRAVES' ORBITOPATHY PATIENTS HIGHLIGHTS THE PRIMACY OF HLA IN AUTOIMMUNE THYROID DISEASETerry F. Davies ABSTRACT # 26 - TRIPLE THERAPY (GLUCOCORTICOID + CICLOSPORIN + ORBITAL IRRADIATION) FOR DIPLOPIA (DIP) OF MODERATE–TO–SEVERE GRAVES' ORBITOPATHY (MSGO). A PROSPECTIVE FOLLOW–UP STUDYPeter Laurberg 4:00 PM – 4:30 PMMonday Short Oral Communications 3Co-Chairs: Virginia Sarapura and W. Edward Visser Southern Hemisphere IIIFifth Level ABSTRACT # 27 - DOT1L, THE H3K79 METHLTRANSFERASE, ACTS AS A NOVEL THYROID HORMONE RECEPTOR CO–ACTIVATORLuan Wen ABSTRACT # 28 - IODINE EXCESS EXPOSURE DURING PREGNANCY/LACTATION IMPAIRS THYROID HORMONES PRODUCTION, METABOLISM AND TRANSPLACENTAL TRANSFER IN RAT DAMSCaroline Serrano Do Nascimento ABSTRACT # 29 - A FULL–LENGTH MODEL OF THE THYROTROPIN RECEPTOR SUPPORTED BY EXPERIMENTAL DATA FROM MASS SPECTROMETRY AND TARGETED RECEPTOR MUTATIONJoerg Schaarschmidt ABSTRACT # 30 - HYPERTHYROID BUT NOT HYPOTHYROID PATIENTS ARE AT HIGHER RISK OF REHOSPITALISATION AND INCREASED CARDIOVASCULAR MORBIDITY–A MATCHED CASE–CONTROL STUDYBarbara Torlinska ABSTRACT # 31 - DETECTION OF NOVEL GENE VARIATIONS IN CONGENITAL HYPOTHYROIDISM WITH TARGETED NEXT–GENERATION SEQUENCINGJukka Kero 4:00 PM – 4:30 PMMonday Short Oral Communications 4Co-Chairs: Elizabeth McAninch and Joao Romaldini Northern Hemisphere A1-A2, Fifth Level ABSTRACT # 32 - RESISTANCE TO THYROID HORMONE (RTH) WITHOUT MUTATIONS IN THE THYROID HORMONE RECEPTOR BETA (THRB) GENE (NONTR–RTH): THE CHICAGO EXPERIENCETheodora Pappa ABSTRACT # 33 - COAGULATION AND FIBRINOLYSIS IN PATIENTS WITH RESISTANCE TO THYROID HORMONE DUE TO A THYROID HORMONE RECEPTOR ß–GENE MUTATIONLaura Elbers ABSTRACT # 34 - DECIPHERING THE POTENTIAL OF 3–IODOTHYROMINE (T1AM) IN REGULATING LIPID METABOLISMFariba Assadi–Porter ABSTRACT # 35 - BISPHENOL–A IN RATS PRESENTS DIFFERENT THYROID HORMONE DISRUPTING PROFILES DEPENDING ON THE WINDOW OF EXPOSUREMaria Izabel Chiamolera ABSTRACT # 36 - MICE WITH GENE INACTIVATION OF α2C–ADRENOCEPTOR ARE RESISTANT TO HYPERTHYROIDISM–INDUCED BONE LOSSMarilia Grecco Teixeira 4:00 PM – 4:30 PMMonday Short Oral Communications 5Co-Chairs: John Al Copland and Markus Eszlinger Northern Hemisphere A3-A4, Fifth Level ABSTRACT # 37 - IDENTIFICATION OF KIAA1217–RET AS A NOVEL FUSION GENE IN PAPILLARY THYROID CANCEREndong Chen ABSTRACT # 38 - P21–ACTIVATED KINASE 4 REGULATES PAPILLARY THYROID CANCER CELL PROLIFERATION, MIGRATION AND INVASIONXiaochen Xie ABSTRACT # 39 - METFORMIN INHIBITS THE PROLIFERATION OF THYROID CANCER STEM CELLS BY UP–REGULATING TUMOR SUPPRESSOR MIRNASGuofang Chen ABSTRACT # 40 - LOSS OF XB130 CAUSES DYSHORMONOGENESIS ASSOCIATED WITH IODIDE ORGANIFICATION DEFECT AND THE DEVELOPMENT OF MULTINODULAR GOITERHae-Ra Cho ABSTRACT # 41 - ETV5, AN ETS FAMILY TRANSCRIPTION FACTOR, IS A MARKER FOR RAS–DEPENDENT THYROID CANCER PROGRESSIONOorvashi Roy Puli 4:00 PM – 4:30 PMMonday Short Oral Communications 6Co-Chairs: Stefan Grebe and Tania Pilli Northern Hemisphere E1-E2, Fifth Level ABSTRACT # 42 - INHIBITION OF MITOCHONDRIAL COMPLEX 4 INCREASES GLUCOSE CONSUMPTION IN THYROID CANCER CELLSKirk E. Jensen ABSTRACT # 43 - HIGHLY EXPRESSED PROTEIN FAM83F INCREASES RESISTANCE TO DOXORUBICIN IN PAPILLARY THYROID CANCERCesar S. Fuziwara ABSTRACT # 44 - UMORIGENIC ROLE OF MICRORNA MIR-17-92 CLUSTER VIA DEREGULATION OF TGFβ SIGNALING PATHWAY IN THYROID FOLLICULAR CELLSCesar S. Fuziwara ABSTRACT # 45 - THE INVITRO EFFECTS OF METFORMIN ON THYROID CANCER CELL LINESSafar Kheder ABSTRACT # 46 - INDUCTION OF THE ONCOTIC DEATH PATHWAY IN THYROID CANCER CELLSAthanasios Bikas 4:00 PM – 4:30 PMMonday Short Oral Communications 7Co-Chairs: Paolo Vitti and Ramona Dadu Northern Hemisphere E3-E4, Fifth Level ABSTRACT # 47 - THE STRATIFICATION OF PATIENT'S RISK DEPENDING ON THE SIZE AND RATIO OF METASTATIC LYMPH NODES IN PAPILLARY THYROID CARCINOMAJa Sung Bae ABSTRACT # 48 - SHEAR–WAVE ELASTOGRAPHY VS FINE–NEEDLE ASPIRATION BIOPSY FOR PREDICTING CANCER IN THYROID NODULES: NO CORRELATION IN PROSPECTIVE STUDY OF 5000 CONSECUTIVE PATIENTSIlya Sleptsov ABSTRACT # 49 - BETHESDA CATEGORIZATION OF THYROID NODULE CYTOLOGY & PREDICTION OF THYROID CANCER TYPE AND PROGNOSISXiaoyun Liu ABSTRACT # 50 - THE FREQUENCY OF HIGH RISK CHARACTERISTICS REQUIRING TOTAL THYROIDECTOMY FOR 1–4 CM WELL DIFFERENTIATED THYROID CANCERWouter Pieter Kluijfhout ABSTRACT # 51 - THE IMPACT OF RET AND RAS MUTATION STATUS ON OVERALL SURVIVAL IN THE EXAM TRIAL, A PHASE 3 STUDY OF CABOZANTINIB (CABO) IN PATIENTS (PTS) WITH PROGRESSIVE, METASTATIC MEDULLARY THYROID CANCER (MTC)Steven I. Sherman 4:00 PM – 4:30 PMMonday Short Oral Communications 8Co-Chairs: Iwao Sugitani and Jennifer Sipos Americas Seminar RoomFifth Level ABSTRACT # 52 - COMPARISON OF EMPIRIC FIXED DOSING WITH A WHOLE BODY/BLOOD CLEARANCE DOSIMETRY BASED MANAGEMENT APPROACH TO RADIOACTIVE IODINE TREATMENT IN PATIENTS WITH RAI AVID DISTANT METASTASES FROM DIFFERENTIATED THYROID CANCERR. Michael Tuttle ABSTRACT # 53 - SECOND PRIMARY MALIGNANCIES IN BELARUS, PATIENTS WITH POST–CHERNOBYL PAPILLARY THYROID CARCINOMAMichael Fridman ABSTRACT # 54 - SUB–CLASSIFICATION OF INDETERMINATE CATEGORIES OF THYROID CYTOPATHOLOGY IMPROVES RISK STRATIFICATION AND COULD BE USED TO SELECT AND INTERPRET THE RESULTS OF MOLECULAR MARKER TESTSPablo Valderrabano ABSTRACT # 55 - OUTCOMES BY SITE OF METASTASIS FOR PATIENTS WITH RADIOIODINE–REFRACTORY DIFFERENTIATED THYROID CANCER TREATED WITH LENVATINIB VERSUS PLACEBO: RESULTS FROM A PHASE 3, RANDOMIZED TRIALMouhammed Habra ABSTRACT # 56 - AMPK OVERACTIVATION IN BCPAP TUMOR CELLS INDUCES CELL DEATH THROUGH INCREASED REACTIVE OXYGEN SPECIES (ROS)Denise Pires De Carvalho 4:30 PM – 5:30 PMHighlighted Oral Abstracts 1Co-Chairs: Yaron Tomer and Tanja Diana Southern Hemisphere IFifth Level ABSTRACT # 1 -STRUCTURE AND ACTIVATION OF THE TRANSMEMBRANE DOMAIN OF THE TSH RECEPTORRicardo Nunez Miguel ABSTRACT # 2 -A UNIQUE HLA-DR POCKET PREDISPOSES TO BOTH AUTOIMMUNE THYROIDITIS AND DIABETES BY PRESENTING THYROID AND ISLET PEPTIDESCheuk Wun Li ABSTRACT # 3 - CHEMICAL CHAPERONES RESCUE THE PATHOGENIC △PHE501 MUTATION IN MONOCARBOXYLATE TRANSPORTER 8Doreen Braun ABSTRACT # 4 - TRANSCRIPTION FACTOR PAIRED–BOX 8 REGULATES NA+/I-SYMPORTER GENE EXPRESSION IN SMALL-INTESTINE ABSORPTIVE ENTEROCYTESJuan Nicola 4:30 PM – 5:30 PMHighlighted Oral Abstracts 2Co-Chairs: Marco Centanni and Rosalind Brown Southern Hemisphere IIFifth Level ABSTRACT # 5 - THYROID FUNCTION AND THE RISK OF DEMENTIA: THE ROTTERDAM STUDYLayal Chaker ABSTRACT # 6 - BMP AND FGF SIGNALING ARE REQUIRED FOR DIRECTED DIFFERENTIATION OF PLURIPOTENT STEM CELLS INTO FUNCTIONAL THYROID FOLLICLESMaria Serra ABSTRACT # 7 - TREATMENT OF HYPOTHYROIDISM WITH LEVOTHYROXINE PLUS TRIIODOTHYRONINE: A RANDOMIZED, DOUBLE–BLIND CROSSOVER STUDYGilberto Paz–Filho ABSTRACT # 8 - ATYPICAL HIPPOCAMPAL FUNCTIONING DURING VERBAL MEMORY RECALL IN YOUTH WITH CONGENITAL HYPOTHYROIDISMJoanne Rovet 4:30 PM – 5:30 PMHighlighted Oral Abstracts 3Co-Chairs: Gerard Doherty and Haixia Guan Northern Hemisphere BCDFifth Level ABSTRACT # 9 - CHARACTERIZATION OF THE CANCER GENOME OF ADVANCED THYROID TUMORS IDENTIFIES DISTINCT MOLECULAR HALLMARKS OF POORLY DIFFERENTIATED AND ANAPLASTIC THYROID CANCERSIñigo Landa ABSTRACT # 10 - A 2015 SURVEY OF ENDOCRINOLOGISTS ON THE MANAGEMENT OF THYROID NODULESNicole Odette Vietor ABSTRACT # 11 - TSH OVERCOMES BRAFV600E–INDUCED SENESCENCE TO PROMOTE TUMOR PROGRESSION VIA DOWN–REGULATION OF P53 EXPRESSION IN PAPILLARY THYROID CANCERYufei Shi ABSTRACT # 12 - SUBCATEGORIZATION OF ATYPIA OF UNDETERMINED SIGNIFICANCE/FOLLICULAR LESION OF UNDETERMINED SIGNIFICANCE (AUS/FLUS): A STUDY APPLYING THYROID IMAGING REPORTING AND DATA SYSTEM (TIRADS)Jung Hyun Yoon 4:30 PM – 5:30 PMHighlighted Oral Abstracts 4Co-Chairs: Ana Maria Masini-Repiso and Joseph Koehrle Southern Hemisphere IIIFifth Level ABSTRACT # 13 - ALTERNATIVE SPLICING OF TRA IS ESSENTIAL TO ORCHESTRATE NORMAL SKELETAL DEVELOPMENT AND ADULT BONE MAINTENANCEJ.H. Duncan Bassett ABSTRACT # 14 - TRAGS AND TRßGS KNOCK–IN MICE DEMONSTRATE PHYSIOLOGICAL RELEVANCE OF NON–CLASSICAL THYROID HORMONE ACTIONSebastian Hönes ABSTRACT # 15 - D2KO ZEBRAFISH AS A NON–MAMMALIAN MODEL TO STUDY THE ROLE OF LOCAL THYROID HORMONE ACTIVATIONVeerle M. Darras ABSTRACT # 16 - THYROID HORMONE ANALOG THERAPY IN PATIENTS WITH THE ALLAN–HERNDON–DUDLEY SYNDROME (AHDS): THE TRIAC TRIALStefan Groeneweg 5:30 PM – 7:00 PMAmerican Thyroid Association (ATA) Annual Business Meeting (for ATA members only) Northern Hemisphere E3-E4, Fifth Level5:30 PM – 7:00 PMAsia and Oceania Thyroid Association (AOTA) Annual Business Meeting (for AOTA members only) Northern Hemisphere E1-E2, Fifth Level5:30 PM – 7:00 PMEuropean Thyroid Association (ETA) Annual Business Meeting (for ETA members only) Northern Hemisphere A1-A2, Fifth Level5:30 PM – 7:00 PMLatin American Thyroid Society (LATS) Annual Business Meeting (for LATS members only) Northern Hemisphere A3-A4, Fifth Level15th International Thyroid Congress Scientific Program – Tuesday, October 206:30 AM – 4:30 PM15th ITC Registration Open Convention Foyer 1/2Lobby/Third Level6:30 AM – 4:30 PMSpeaker Ready Room Open (open to meeting faculty only) Australia 2 RoomLobby/Third Level6:30 AM – 8:00 AMEarly Riser Symposium Continental Breakfast Pacific HallGround/First Level7:00 AM – 8:20 AMEarly Riser Symposium: Differences Between Pediatric and Adult Differentiated Thyroid CancerChair: Rossana Corbo Pacific HallGround/First Level Thyroid Cancer PhenotypesSylvia L. Asa Approach to Radioiodine TreatmentChristoph Reiners Thyroid Cancer OutcomeFernanda Vaisman Thyroid Cancer GuidelinesSteven G. Waguespack 8:35 AM – 9:20 AMPlenary Lecture: Choice of Therapy for Graves' HyperthyroidismIntroduction by Furio PaciniLuigi BartalenaNorthern Hemisphere BCDFifth Level9:00 AM – 4:00 PM15th ITC Exhibit and Poster Hall Open(Open at 8:00 AM for poster presenters only) Atlantic HallGround/First Level9:20 AM – 9:45 AMPoster Review Session and Break in the Exhibit Hall Atlantic HallGround/First Level9:30 AM – 11:00 AMRidgway Trainee Conference Clinical Track: Case Discussions – Thyroid Nodule (Open to all trainees)Susan J. MandelLaszlo HegedusHans GrafSouthern Hemisphere IV-VFifth Level9:45 AM – 11:00 AMTuesday Basic Oral Abstracts 1: Thyroid Cancer Genetics/GenomicsCo-Chairs: Rafaelle Ciampi and Rebecca Schweppe Southern Hemisphere IFifth Level ABSTRACT # 57 - ASSOCIATION BETWEEN TERT PROMOTER AND NRAS MUTATIONS AND THEIR COOPERATIVE UP–REGULATION OF TERT EXPRESSIONRengyun Liu ABSTRACT # 58 - A NOVEL MECHANISM INVOLVING WIPF1 OVEREXPRESSION VIA PROMOTER HYPOMETHYLATION BY BRAF V600E IN THYROID TUMORIGENESISTao Zhang ABSTRACT # 59 - NEXT GENERATION SEQUENCING MUTATION PROFILING REVEALS NOVEL PUTATIVE TUMOR CANDIDATES IN ANAPLASTIC THYROID CARCINOMASören Latteyer ABSTRACT # 60 - HABP2 IS A NOVEL TUMOR SUPPRESSOR GENE THAT CAUSES FAMILIAL NONMEDULLARY THYROID CANCERSudheer Kumar Gara ABSTRACT # 61 - A CHEMICAL PROTEOMICS APPROACH TO IDENTIFY MECHANISMS OF RESISTANCE TO THE SRC INHIBITOR, DASATINIBKatie Marie Mishall 9:45 AM – 11:00 AMTuesday Basic Oral Abstracts 2: Thyroid Signaling Metabolism and ActionCo-Chairs: Sheue-yann Cheng and Juan Nicola Southern Hemisphere IIFifth Level ABSTRACT # 62 - MESENCHYMAL STEM CELL–MEDIATED SODIUM IODIDE SYMPORTER (NIS) GENE DELIVERY IN A MOUSE MODEL OF PANCREATIC DUCTAL ADENOCARCINOMA USING NIS AS REPORTER GENEChristina Schug ABSTRACT # 63 - USING THE HYPOXIA RESPONSE NETWORK FOR TUMOUR-TARGETED 131I THERAPY OF ORTHOTOPIC HEPATOCELLULAR CARCINOMA (HCC) XENOGRAFTS AFTER MESENCHYMAL STEM CELL (MSC)-MEDIATED SODIUM IODIDE SYMPORTER (NIS) GENE DELIVERYAndrea Mueller ABSTRACT # 64 - ROLE AND MECHANISM OF TYPE 2 IODOTHYRONINE DEIODINASE UBIQUITINATION OF PITUITARY IN IODINE INDUCED TSH ELEVATIONXiaowen Zhang ABSTRACT # 65 - THYROID HORMONE SIGNALING REGULATES ENDOGENOUS HYDROGEN SULFIDE PRODUCTIONHyo–jeong Kim ABSTRACT # 66 - MEMBRANE-TRAVERSING MECHANISM FOR THYROID HORMONE TRANSPORT AT MCT8Gerd Krause 9:45 AM – 11:00 AMTuesday Clinical Oral Abstracts 1: Autoimmunity and PregnancyCo-Chairs: Yasumasa Iwasaki and Maria Cabanillas Northern Hemisphere BCDFifth Level ABSTRACT # 67 - MATERNAL THYROID FUNCTION DURING EARLY PREGNANCY IS ASSOCIATED WITH TOTAL CEREBRAL GRAY MATTER AND CORTEX VOLUME IN SCHOOL-AGE CHILDRENTim Korevaar ABSTRACT # 68 - CLINICAL RELEVANCE OF THYROID STIMULATING ANTIBODIES IN HASHIMOTO'S THYROIDITIS AND ASSOCIATED ORBITOPATHYGeorge J. Kahaly ABSTRACT # 69 - THE NATURAL HISTORY OF SUBCLINICAL HYPERTHYROIDISM DUE TO GRAVES' DISEASE – THE RULE OF THIRDSSalman Razvi ABSTRACT # 70 - EFFECTS OF LEVOTHYROXINE THERAPY ON PREGNANCY OUTCOMES IN WOMEN WITH SUBCLINICAL HYPOTHYROIDISMSpyridoula Maraka ABSTRACT # 71 - THYROID HORMONE LEVELS IN NORMAL PREGNANT WOMEN: THE INFLUENCE OF BODY MASS INDEXLorena Mosso 9:45 AM – 11:00 AMTuesday Clinical Oral Abstracts 2: Thyroid Cancer TherapyCo-Chairs: Duncan Topliss and Sara Ahmadi Southern Hemisphere IIIFifth Level ABSTRACT # 72 - OUTCOMES IN RESPONSE TO AGGRESSIVE MULTIMODAL THERAPY IN ANAPLASTIC THYROID CANCER: THE MAYO CLINIC EXPERIENCEAditi Kumar ABSTRACT # 73 - CABOZANTINIB IN PATIENTS WITH RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCER WHO PROGRESSED ON PRIOR VEGFR-TARGETED THERAPY: RESULTS OF NCI- AND ITOG-SPONSORED MULTICENTER PHASE II CLINICAL TRIALManisha H. Shah ABSTRACT # 74 - RECENT CHANGES IN THE CLINICAL OUTCOME OF PAPILLARY THYROID CARCINOMA WITH CERVICAL LYMPH NODE METASTASISMin Ji Jeon ABSTRACT # 75 -LONG–TERM OUTCOME OF LOCALIZED THYROID MUCOSA-ASSOCIATED LYMPHOID TISSUE LYMPHOMA: RETROSPECTIVE ANALYSIS OF 106 CONSECUTIVE CASESNatsuko Watanabe ABSTRACT # 76 - TREATMENT OF CHILDHOOD AND ADOLESCENT THYROID CANCER IN FUKUSHIMA AFTER FUKUSHIMA DAIICHI NUCLEAR POWER PLANT ACCIDENT ON MARCH 11, 2011Shinichi Suzuki 11:00 AM – 11:50 AMDD11 – Discussion/Debates Clinical: How Reliable are Free Thyroid Hormone Assays?Stefan Karl Guenther GrebeSteven SoldinSouthern Hemisphere IIIFifth Level11:00 AM – 11:50 AMDD12 – Discussion/Debates Clinical: Rituximab Therapy for Graves' OrbitopathyMario G. SalviMarius N. StanNorthern Hemisphere A1-A2, Fifth Level11:00 AM – 11:50 AMDD13 – Discussion/Debates Clinical: Maternal Isolated Hypothyroxinemia: What Do We Know and What Do We Not Know?Marco MediciChrysoula DosiouSouthern Hemisphere IFifth Level11:00 AM – 11:50 AMDD14 – Discussion/Debates Clinical: Is it Possible to Improve Outcomes in Congenital Hypothyroidism?Stephen H. LaFranchiToni TorresaniAsia 2 RoomLobby/Third Level11:00 AM – 11:50 AMDD15 – Discussion/Debates Clinical: Emerging Concepts In The Management of Recurrent Thyroid CancerKenneth D. BurmanEnrico PapiniNorthern Hemisphere BCDFifth Level11:00 AM – 11:50 AMDD16 – Discussion/Debates Basic/Translational: Clinical and Basic Aspects of Bone Turnover by Thyroid HormoneJohn G. LoganBente LangdahlNorthern Hemisphere E1-E2, Fifth Level11:00 AM – 11:50 AMDD17 – Discussion/Debates Basic/Translational: Roles of TSH from Pars Tuberalis and Pars DistalisTakashi YoshimuraNorthern Hemisphere A3-A4, Fifth Level11:00 AM – 11:50 AMDD18 – Discussion/Debates Basic/Translational: Thyroid Function and Metabolic SyndromeGabriela BrentaJiajun ZhaoAmericas Seminar RoomFifth Level11:00 AM – 11:50 AMDD19 – Discussion/Debates Basic/Translational: Deiodinases and CancerStephen A. HuangDomenico SalvatoreNorthern Hemisphere E3-E4, Fifth Level11:00 AM – 11:50 AMDD20 – Discussion/Debates Basic/Translational: TSHR StructureJane SandersRicardo Nunez MiguelAsia 1 RoomFifth Level12:00 PM – 1:00 PMPoster Review Session and Lunch in the Exhibit Hall Atlantic HallGround/First Level12:00 PM – 1:30 PMRidgway Trainee Conference Clinical Track Lunch Session: Setting Up a Thyroid Practice (Open to all trainees; lunch ticket required for meal)Brittany Bohinc HendersonMark A. LupoSouthern Hemisphere IV-VFifth Level12:00 PM – 1:00 PMRidgway Trainee Conference Basic Track Lunch Session: Genome Editing with CRISPR/Cas9 and TALEN Nucleases (Open to all trainees; lunch ticket required for meal)Daniel BuchholzAsia 3 RoomLobby/Third Level12:00 PM – 1:00 PM15th ITC Expo Theater Presented by Veracyte, Inc.(Limited seating; first-come, first-served; lunch included) Atlantic HallGround/First Level1:00 PM – 1:30 PMTuesday Short Oral Communications 1Co-Chairs: Anja Eckstein and Ulla Feldt-Rasmussen Southern Hemisphere IFifth Level ABSTRACT # 77 - ASSOCIATIONS OF POLYMORPHISMS IN GENE ENCODING PRI-MIR-125A AND THE MATURE MIR-125A EXPRESSION WITH THE PROGNOSIS OF AUTOIMMUNE THYROID DISEASESMikio Watanabe ABSTRACT # 78 - CXCL10, CXCL9, AND CXCL11 α-CHEMOKINES CIRCULATING LEVELS ARE INCREASED IN GRAVES' OPHTHALMOPATHY PATIENTS, AND REDUCED BY CORTICOSTEROIDS TREATMENTAlessandro Antonelli ABSTRACT # 79 - GLUCOCORTICOID RECEPTOR, NF-KB, AND AP-1 EXPRESSION IN ORBITAL FAT AND EXTRAOCULAR MUSCLE IN PATIENTS WITH GRAVES' ORBITOPATHYAdriano Cury ABSTRACT # 80 - VITAMIN-D SUPPLEMENTATION REDUCES THYROID PEROXIDASE ANTIBODY LEVELS IN PATIENTS WITH AUTOIMMUNE THYROID DISEASE: AN OPEN LABELED RANDOMIZED
Referência(s)